BSE filing, NSE: RADICO. Summary written from the filing by ALFA Finder's alert engine.
Radico Khaitan Ltd: key numbers
- Share price
- ₹4,135.10
- Market cap
- ₹55,406 Cr
- Revenue (annual)
- ₹6,050 Cr
- Net profit (annual)
- ₹604.5 Cr
- P/E (TTM)
- 69.6×Sector 26.2×
- Promoter holding
- 40.17%-0.02% QoQ
- FII holding
- 19.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Radico Khaitan Ltd
All →Radico Khaitan ED Probe / Tax Survey
Radico Khaitan disclosed that DRI officials visited its New Delhi office and Rampur plant on October 26, 2026, under the Customs Act. The company reports no current financial or operational impact and is cooperating fully.
Radico Khaitan Management Change
Radico Khaitan appoints CFO Dilip Kumar Banthiya as Executive Director effective October 28, 2026. Saket Somani is elevated to Deputy Chief Financial Officer.
Radico Khaitan Q2 FY27 Results: Net Profit ₹232.3 Cr, Up 66.4% YoY
Radico Khaitan Ltd reported revenue from operations of ₹5,583 Cr (+10.4% YoY) and net profit of ₹232.3 Cr (+66.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹232.3 Cr · +66.4% YoY
Radico Khaitan Other Announcement
Radico Khaitan Limited received an ESG rating score of 69 from NSE Sustainability Ratings and Analytics Limited. This unsolicited rating was based on the company's independent public disclosures.
Radico Khaitan Earnings Call Transcript: Key Takeaways
Radico reports a record quarter led by premiumization, with the P&A segment delivering a staggering 36% volume growth.
- Call
- Guides 25% growth
Radico Khaitan Board Meeting Date
Radico Khaitan Ltd will hold a board meeting on October 27, 2026, to approve the financial results for the quarter and half year ended September 30, 2026.
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.